Senti Biosciences is trading 6.75% down in pre-market at $0.30; no confirmed October 9 company announcement explaining the move surfaced in available search results. - An October 8 shareholder meeting was scheduled to consider the Celadon merger and a possible reverse split; its outcome is unreported, and the agenda alone does not establish a cause. - A September SEC filing describes potential substantial share dilution and going-concern risks, but is not a new October 9 catalyst. - Major U.S. indices are higher in the supplied pre-market context; no broad-market explanation is established.